A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
- 1 May 1991
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 83 (5) , 1534-1542
- https://doi.org/10.1161/01.cir.83.5.1534
Abstract
This study addressed the need for heparin administration to be continued for more than 24 hours after coronary thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). A total of 241 patients with acute myocardial infarction were treated with 100 mg rt-PA and a bolus of 5,000 units i.v. heparin followed by 1,000 units/hr i.v. heparin for 24 hours. At 24 hours, 202 patients were randomized to continue intravenous heparin therapy (n = 99) in full dosage or to discontinue heparin therapy and begin an oral antiplatelet regimen of aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103). On prospective recording, there were no differences in the pattern of chest pain, reinfarction, or bleeding complications. Coronary angiography on cardiac catheterization at 7-10 days showed no differences in patency of the infarct-related artery. The proportion of patients with total occlusion (TIMI grade 0-1) of the infarct-related artery was 18.9% in the heparin group and 19.8% in the aspirin and dipyridamole group. In the patients with an incompletely occluded infarct-related artery, the lumen was reduced by 69 +/- 2% of normal in the heparin group and 67 +/- 2% in the aspirin and dipyridamole group. Left ventricular function assessed on cardiac catheterization and radionuclide study at day 2 and at 1 month showed no differences between the two groups. Left ventricular ejection fraction on radionuclide ventriculography at 1 month was 52.4 +/- 1.2% in the heparin group and 51.9 +/- 1.2% in the aspirin and dipyridamole group. We conclude that heparin therapy can be discontinued 24 hours after rt-PA therapy and replaced with an oral antiplatelet regimen without any adverse effects on chest pain, reinfarction, coronary patency, or left ventricular function.Keywords
This publication has 13 references indexed in Scilit:
- Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarctionThe American Journal of Cardiology, 1990
- A Comparison between Heparin and Low-Dose Aspirin as Adjunctive Therapy with Tissue Plasminogen Activator for Acute Myocardial InfarctionNew England Journal of Medicine, 1990
- In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparinThe Lancet, 1990
- Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.BMJ, 1988
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Recombinant tissue plasminogen activator (rt-PA): Is it the thrombolytic agent of choice for an evolving acute myocardial infarction?The American Journal of Cardiology, 1987
- Role of heparin after intravenous thrombolytic therapy for acute myocardial infarctionThe American Journal of Cardiology, 1987
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Effect of interventions in salvaging left ventricular function in acute myocardial infarction: A study of intracoronary streptokinaseThe American Journal of Cardiology, 1983